Opinion|Videos|September 26, 2024
Looking to the Future of Red Light Therapy
Author(s)Aaron S. Farberg, MD
Panelists discuss how red light therapy has emerged as a versatile, noninvasive treatment in aesthetic dermatology, offering benefits such as collagen stimulation and skin rejuvenation while comparing favorably with other cosmetic treatments in terms of minimal adverse effects and high patient satisfaction rates.
Advertisement
Episodes in this series
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
5